At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the multicentre, open-label, randomised phase 3 ENDEAVOR study of carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed multiple myeloma.
ENDEAVOR: A phase 3 study of carfilzomib in relapsed myeloma
26th June 2015
Hematology
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now